Royalty Pharma PLC RPRX
58.21
0.56
0.97%
as of 25 Sep
- Market cap
- $34.4B
- P/E
- 40.1×
Follow RPRX
Growth Flags
show if company had growth for consecutive years
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
Revenue |
2,378.19 | 2,263.58 | 2,354.55 | 2,237.22 | 2,289.46 | 2,122.35 | 1,814.25 | 1,794.89 |
Revenue Growth |
5.06% | (3.86%) | 5.24% | (2.28%) | 7.87% | 16.98% | 1.08% | (1.07%) |
Gross Profit |
2,378.19 | 2,263.58 | 2,354.55 | 2,237.22 | 2,289.46 | 2,122.35 | 1,814.25 | 1,794.89 |
R&D Expenses |
452.00 | 2.00 | 52.00 | 177.11 | 200.08 | 26.29 | 83.04 | 392.61 |
SG&A Expenses |
573.48 | 236.67 | 249.75 | 227.30 | 182.83 | 181.72 | 103.44 | 61.91 |
Operating Income |
1,559.52 | 1,292.44 | 1,492.15 | 307.07 | 1,430.72 | 1,595.40 | 2,623.18 | 1,364.45 |
Non-operating Income/Expense |
(235.33) | 38.37 | 207.94 | (77.00) | (189.51) | 106.56 | (161.76) | 153.41 |
Non-operating Interest Expenses |
307.66 | 225.51 | 187.19 | 187.96 | 166.14 | 157.06 | 268.57 | 279.96 |
| 1,324.19 | 1,330.81 | 1,700.09 | 230.06 | 1,241.20 | 1,701.95 | 2,461.42 | 1,517.86 | |
Income after Tax |
1,324.19 | 1,330.81 | 1,700.09 | 230.06 | 1,241.20 | 1,701.95 | 2,461.42 | 1,517.86 |
Dividends (Preferred) |
— | 0.00 | — | — | — | — | — | — |
Non-Controlling Interest |
553.25 | 471.83 | 565.25 | 187.23 | 621.47 | 726.91 | 112.88 | 140.13 |
Net Income Common |
770.95 | 858.98 | 1,134.83 | 42.83 | 619.73 | 975.04 | 2,348.54 | 1,377.73 |
EPS (Basic) |
1.37 | 1.45 | 1.88 | 0.07 | 1.02 | 1.61 | 6.56 | — |
EPS (Diluted) |
1.37 | 1.45 | 1.88 | 0.07 | 1.02 | 1.61 | 6.56 | — |
Shares (Basic, Weighted) |
429.80 | 448.19 | 447.60 | 437.96 | 414.79 | 375.44 | 375.44 | — |
Shares (Diluted, Weighted) |
564.46 | 594.11 | 602.90 | 437.97 | 414.80 | 375.46 | 375.46 | — |
Gross Margin |
100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
EBIT Margin |
65.58% | 57.10% | 63.37% | 13.73% | 62.49% | 75.17% | 144.59% | 76.02% |
EBT margin |
55.68% | 58.79% | 72.20% | 10.28% | 54.21% | 80.19% | 135.67% | 84.57% |
Net Profit Margin |
32.42% | 37.95% | 48.20% | 1.91% | 27.07% | 45.94% | 129.45% | 76.76% |
Free Cash Flow Margin |
104.69% | 121.53% | 126.89% | 94.88% | (7.60%) | (6.96%) | (2.98%) | 75.14% |
EBITDA |
1,592.01 | 1,312.01 | 1,512.65 | 334.09 | 1,473.87 | 1,630.17 | 2,659.89 | 1,410.84 |
EBIT |
1,559.52 | 1,292.44 | 1,492.15 | 307.07 | 1,430.72 | 1,595.40 | 2,623.18 | 1,364.45 |
Income from Continuous Operations |
1,324.19 | 1,330.81 | 1,700.09 | 230.06 | 1,241.20 | 1,701.95 | 2,461.42 | 1,517.86 |
Consolidated Net Income/Loss |
1,324.19 | 1,330.81 | 1,700.09 | 230.06 | 1,241.20 | 1,701.95 | 2,461.42 | 1,517.86 |
EPS (Basic, from Continuous Ops) |
3.08 | 2.97 | 3.80 | 0.53 | 2.99 | 4.53 | 6.56 | — |
EPS (Basic, Consolidated) |
3.08 | 2.97 | 3.80 | 0.53 | 2.99 | 4.53 | 6.56 | — |
EPS (Diluted, from Cont. Ops) |
2.35 | 2.24 | 2.82 | 0.53 | 2.99 | 4.53 | 6.56 | — |
Shares (Diluted, Average) |
564.00 | 594.00 | 603.00 | 607.00 | 607.00 | 607.00 | — | — |
EPS (Diluted, Consolidated) |
2.35 | 2.24 | 2.82 | 0.53 | 2.99 | 4.53 | 6.56 | — |
EBITDA Margin |
66.94% | 57.96% | 64.24% | 14.93% | 64.38% | 76.81% | 146.61% | 78.60% |
Operating Cash Flow Margin |
104.69% | 122.33% | 126.89% | 95.83% | 88.12% | 95.87% | 91.90% | 90.16% |
In millions of $ except per-share values · columns are period end dates